Knowledge Library

OncoWuXi Express: PSMA Overexpressing PC3 Tumor Model

Introduction: OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share with you the newly established PSMA-overexpressing PC3 prostate cancer model. https://onco.wuxiapptec.com Globally, prostate cancer stands not only …Read More >

Resource Type: Article Blog
Resource Topic: Oncology Tumor Models

VIEW

AACR 2024 Posters: Sneak Peek

AACR 2024 Sneak Peek | Your All-In-One Guide to WuXi Biology’s Latest Advances in Cancer Research The American Association for Cancer Research (AACR) Annual Meeting 2024, one of the largest global cancer research conferences, will take place from April 5 to 10 at the San Diego Convention Center. This year, WuXi Biology has been selected …Read More >

Resource Type: Article Blog
Resource Topic: CAR-T Cell Oncology Oncolytic Viruses Tumor Models

VIEW

T-DXd Resistant Tumor Models with ABCG2

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed, and development of next generation ADCs necessitates the establishment of resistant tumor models.  One mechanism of resistance involves efflux of the ADC payload by the transporter …Read More >

Resource Type: Presentation
Resource Topic: Antibody Drug Conjugate Oncology Tumor Models

VIEW

OncoWuXi Express: Adenovirus Vaccine AD5-HPV Inhibits Tumor Growth by Stimulating Immunity

OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we share with you our experience in the establishment and antitumor efficacy evaluation of adenovirus vaccine AD5-HPV. https://onco.wuxiapptec.com Introduction: Adenoviruses (Ad) are non-enveloped …Read More >

Resource Type: Article Blog Case Study
Resource Topic: Oncology Tumor Models

VIEW

Establishment of EGFR TKI-Resistant Tumor Models

Despite improvement in clinical outcomes observed with the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs), long-term prognosis remains unfavorable due to the development of either intrinsic or acquired resistance.  Understanding the mechanisms underlying this resistance is vital for designing strategies to address this challenge, and one approach involves the establishment of …Read More >

Resource Type: Latest Science Poster
Resource Topic: Oncology Tumor Models

VIEW

iMN041: Prodrug with a Unique Antitumor Immune Response

WuXi AppTec scientists contributed to a research article in the journal Translational Medicine Communications which characterized the antitumor immune responses generated by iMN041, a prodrug of a DNA methyl transferase/ribonucleotide reductase inhibitor.  This study also assessed the efficacy of iMN041 in mouse xenografts of human clear cell renal cell cancer, pancreatic cancer, and triple negative …Read More >

Resource Type: Latest Science Publication
Resource Topic: Cell-based Assays Immunology Oncology Tumor Models

VIEW

EML4-ALK Cell Lines and In Vivo Models

The EML4-ALK fusion gene occurs in approximately 5% of non-small-cell lung cancers (NSCLCs), making this oncogene an important drug target.  The development of ALK tyrosine kinase inhibitors (ALK-TKIs) has been a major advance in treating NSCLC with this fusion gene, but acquired resistance to ALK-TKIs ultimately limits their use.  To support the development of next-generation …Read More >

Resource Type: Latest Science Presentation
Resource Topic: Cells and Protein Science Oncology Tumor Models

VIEW

High-Dimensional Flow Cytometry Platform

High-dimensional (HD) flow cytometry allows researchers to perform deep phenotyping of immune cells at the single cell level with increased accuracy and sensitivity.  This technology enables complex pathway characterization and data integration for the identification of biomarkers used in immunotherapy.  WuXi AppTec offers a comprehensive panel of HD flow cytometry services, with more than 100 …Read More >

Resource Type: Latest Science Presentation
Resource Topic: Autoimmune and Inflammatory Diseases Biomarkers Oncology Phenotypic Assays

VIEW

STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts

The contribution of the X-ray crystallography team from our WuXi AppTec site in Germany was acknowledged in a recent study published in the journal Cancer Discovery. In this study, the authors show that compound STX-478, an allosteric PI3Kα inhibitor, selectively targets prevalent PI3Kα helical- and kinase-domain mutant tumors. STX-478 demonstrated robust efficacy in human tumor …Read More >

Resource Type: Latest Science Publication
Resource Topic: Oncology Small Molecules Structural Biology Structural Biology X-ray Crystallography

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!